Physician
CDR Health Care INC
CDR Health Care INC was paid $1.30M by Medicaid between Oct 2020 and Dec 2024, across 44 billing codes. Its largest line is 87426, Infectious agent antigen detection, SARS-CoV-2 (COVID-19) — 39% of everything it billed.
33Billing provider infoCDR HEALTH CARE INC
TALLAHASSEE, FL 32308
TALLAHASSEE, FL 32308
33aNPI1497352587assigned 10/02/2020
33bProvider typeFamily Medicine Physician
28Total paid$1.30M
24GClaims110,855
24DCodes billed44
24AFirst – last monthOct 2020 – Dec 2024
Compared with peers
Next to other Family Medicine Physician providers in Florida
Rank by total paid#46 of 996
Median peer was paid$13K
This provider vs. median98×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2020 | 1,401 | $349.39 | |
| 2021 | 39,391 | $464K | |
| 2022 | 65,652 | $793K | |
| 2023 | 633 | $12K | |
| 2024incomplete | 3,778 | $28K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 39% | 31,012 | 19,182 | $503K |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | 24% | 3,391 | 2,535 | $309K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 17% | 14,439 | 10,520 | $219K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 13% | 36,032 | 21,057 | $170K |
| Q0247 | Injection, sotrovimab, 500 mg | 2.7% | 42 | 33 | $35K |
| 91322 | 1.1% | 382 | 360 | $14K | |
| 90480 | <1% | 615 | 565 | $11K | |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | <1% | 759 | 675 | $11K |
| M0245 | Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring | <1% | 49 | 46 | $7K |
| M0240 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring, subsequent repeat doses | <1% | 42 | 33 | $5K |
| M0247 | Intravenous infusion, sotrovimab, includes infusion and post administration monitoring | <1% | 113 | 94 | $4K |
| 0003A | <1% | 933 | 647 | $2K |
32 more codes
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 174 | $2K |
| M0201 | Administration of pneumococcal, influenza, hepatitis b, and/or covid-19 vaccine inside a patient's home; reported only once per individual home per date of service when such vaccine administration(s) are performed at the patient's home | <1% | 1,507 | $1K |
| 0001A | <1% | 269 | $1K | |
| 90688 | <1% | 319 | $791.00 | |
| 90658 | <1% | 101 | $723.62 | |
| 0002A | <1% | 63 | $572.27 | |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 21 | $462.48 |
| 99072 | <1% | 16,042 | $394.01 | |
| Q0243 | Injection, casirivimab and imdevimab, 2400 mg | <1% | 458 | $270.00 |
| 0013A | <1% | 49 | $200.00 | |
| 91320 | <1% | 37 | $143.52 | |
| 0011A | <1% | 26 | $80.00 | |
| Q0244 | Injection, casirivimab and imdevimab, 1200 mg | <1% | 1,467 | $0.04 |
| 90710 | 0% | 118 | $0.00 | |
| 91300 | 0% | 487 | $0.00 | |
| 91321 | 0% | 96 | $0.00 | |
| 90707 | 0% | 127 | $0.00 | |
| 90713 | 0% | 169 | $0.00 | |
| 90700 | 0% | 76 | $0.00 | |
| 90648 | 0% | 72 | $0.00 | |
| 90633 | 0% | 399 | $0.00 | |
| 90715 | 0% | 131 | $0.00 | |
| 90661 | 0% | 33 | $0.00 | |
| Q0245 | Injection, bamlanivimab and etesevimab, 2100 mg | 0% | 27 | $0.00 |
| 90716 | 0% | 265 | $0.00 | |
| 90744 | 0% | 117 | $0.00 | |
| 90651 | 0% | 61 | $0.00 | |
| G0008 | Administration of influenza virus vaccine | 0% | 85 | $0.00 |
| 90677 | 0% | 198 | $0.00 | |
| 90619 | 0% | 18 | $0.00 | |
| Q0240 | Injection, casirivimab and imdevimab, 600 mg | 0% | 16 | $0.00 |
| 90656 | 0% | 18 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialVIDAL-DUART, TINA (CHIEF EXECUTIVE OFFICER)